Matricelf Ltd Asset Resilience Ratio
Matricelf Ltd asset resilience ratio. Matricelf Ltd (MTLF) has an Asset Resilience Ratio of 64.57% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MTLF liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Matricelf Ltd (2022–2024)
Asset resilience ratio of Matricelf Ltd from 2022 to 2024. This chart shows how Matricelf Ltd's Asset Resilience Ratio has changed over time. See MTLF financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Matricelf Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MTLF total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA11.85 Million | 64.57% |
| Total Liquid Assets | ILA11.85 Million | 64.57% |
Asset Resilience Insights
- Very High Liquidity: Matricelf Ltd maintains exceptional liquid asset reserves at 64.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Matricelf Ltd Industry Peers by Asset Resilience Ratio
Compare Matricelf Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Matricelf Ltd Asset Resilience Ratio by Year (2022–2024)
Matricelf Ltd asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Matricelf Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 64.57% | ILA11.85 Million ≈ $31.77K |
ILA18.35 Million ≈ $49.20K |
-5.27pp |
| 2023-12-31 | 69.84% | ILA21.09 Million ≈ $56.55K |
ILA30.20 Million ≈ $80.98K |
-9.01pp |
| 2022-12-31 | 78.85% | ILA31.14 Million ≈ $83.49K |
ILA39.49 Million ≈ $105.88K |
-- |
About Matricelf Ltd
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. Matricelf Ltd was incorporated in 20… Read more